OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Neurodegeneration is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	493
Retraction Note: Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5– implications for dementia with lewy bodies	251
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	251
LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome	249
Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer’s disease through disrupted regulated intramembrane proteolysis	232
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	215
Molecular hallmarks of excitatory and inhibitory neuronal resilience to Alzheimer’s disease	206
Regulation of the hippocampal translatome by Apoer2-ICD release	203
Tau interactome and RNA binding proteins in neurodegenerative diseases	178
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	164
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	160
Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer’s disease genetic pathways	146
Microglia sensing of peripheral signals that bridge the brain and body	130
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration	120
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	118
Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model	115
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	107
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	104
Death-associated protein kinase 1-dependent SENP1 degradation increases tau SUMOylation and leads to cognitive dysfunction in a mouse model for tauopathy	101
Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases	100
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	100
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	96
Recombinant cathepsins B and L promote α-synuclein clearance and restore lysosomal function in human and murine models with α-synuclein pathology	96
Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	92
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	91

HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	88
Multi-region brain transcriptomic analysis of amyotrophic lateral sclerosis reveals widespread RNA alterations and substantial cerebellum involvement	87
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	85
Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	85
The role of NURR1 in metabolic abnormalities of Parkinson’s disease	81
Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition	81
Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	80
In Memoriam of Edward H. Koo, MD 1954–2025	77
Correction: Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	75
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	74
Autophagic impairment in sleep–wake circuitry is linked to sleep loss at the early stages of Alzheimer’s disease	71
Combination therapy using GDNF and cell transplant in Parkinson’s disease	69
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	65
Entering the era of precision medicine to treat amyotrophic lateral sclerosis	64
Repetitive transcranial magnetic stimulation alleviates motor impairment in Parkinson’s disease: association with peripheral inflammatory regulatory T-cells and SYT6	64
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	63
BAX activation in mouse retinal ganglion cells occurs in two temporally and mechanistically distinct steps	63
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease	63
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	63
Clinical progression and genetic pathways in body-first and brain-first Parkinson’s disease	61
Correction: The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	57
ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses	57
A perspective on Alzheimer’s disease: exploring the potential of terminal/paradoxical lucidity and psychedelics	57
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function	56
Deficits in mitochondrial TCA cycle and OXPHOS precede rod photoreceptor degeneration during chronic HIF activation	55
Evidence suggesting that microglia make amyloid from neuronally expressed APP: a hypothesis	54
Using mass spectrometry to validate mouse models of tauopathy	54
The PKCι-β-arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer’s disease	53
Correction: HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	53
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	53
Dementia with lewy bodies patients with high tau levels display unique proteome profiles	53
Methylome analysis of FTLD patients with TDP-43 pathology identifies epigenetic signatures specific to pathological subtypes	53